

ASX ANNOUNCEMENT

ADMEDUS APPOINTS JOHN SEABERG AS CHAIRMAN

Brisbane, Australia 14th of March 2017

Admedus Limited (ASX:AHZ) today announced that John Seaberg has been appointed as the company's Chairman effective immediately. He succeeds Wayne Paterson, who is stepping down, as compliance with the ASX Corporate Governance Principles and Recommendations requires a separation of duties between the CEO and Chairman. Accordingly, Paterson will focus exclusively on the CEO role.

Seaberg first joined the Admedus Board in 2014, from which time he has played a key role in its 'Code Red' turnaround. Most recently, he served as Chairman of the Board of Synovis Life Technologies, a Minneapolis-based manufacturer of various medical devices and bio scaffold tissue products. From 2008 until its sale to Baxter International in 2012, Seaberg served as chairman of the nominating and governance committee, and member of the audit committee.

"John Seaberg and I have been working closely together on the board to position and prepare Admedus for the opportunities ahead – to get the company on a commercially viable pathway," says Paterson. "John's unique blend of impeccable board credentials, senior corporate experience, subject matter expertise – plus wealth of commercial and medical knowledge – have helped prepare Admedus for sustained success in our target markets which he knows like the back of his hand."

Seaberg says: "I am honoured to serve as Chairman of Admedus and am very optimistic about the potential of the Company now that we are on track for profitable growth. I plan to help accelerate the momentum of our progress by working closely with Wayne and the entire Admedus team to secure our objectives. I am particularly excited about ADAPT®, our next generation regenerative tissue engineering platform, on which we are building a superior product portfolio with CardioCel® our flagship as well as some of our more speculative opportunities such as TAVR."

JOHN SEABERG

From 2007 until May 2014, Seaberg was Founder, Chairman and CEO of NeoChord Inc., a venture capital-backed company commercialising technology developed at the Mayo Clinic for the repair of the mitral valve via minimally invasive techniques.

Previously, he was with Guidant Corp. from 1996 until 2006 (subsequently acquired by Boston Scientific Corp.). During his tenure at Guidant, Seaberg served in various executive-level positions in sales and marketing, including Director of Bradycardia Marketing for Cardiac Rhythm Management, Vice President of Sales for Cardiac Surgery, and Vice President of Sales for Cardiac Rhythm Management, where he managed a field sales team of more than 600 people and over \$1 billion in revenue.

In 1991, Seaberg co-founded ACIST Medical and served as its first President and CEO. ACIST manufactures and distributes power injection technologies for coronary angiography and was acquired by Bracco Ltd for \$105 million in 2001. Earlier, he was also the founder and CEO of Seaberg Medical, a regional distributor of implantable cardiovascular devices.

Seaberg lives in Minneapolis. He holds a Bachelor of Arts in Speech Communications from the University of Minnesota and a Masters in Business Administration (MBA) from the Carlson School of Management, also at the University of Minnesota.

Follow us:

Twitter: @Admedus

Facebook: www.facebook.com/pages/Admedus

Website: www.admedus.com

For more information, please contact:

Dr Julian Chick | Chief Operating Officer | Admedus Limited

Tel: +61 (0)8 9266 0100

Signal Leadership Communication Inc.

Mr Bob Pickard

Tel: +1 (647) 822 1000

bob.pickard@signaleadership.com

Media Europe

FTI Consulting

Simon Conway / Victoria Foster Mitchell

Tel: +44 (0) 20 3727 1000

admedus@fticonsulting.com

US Investor

Rx Communications Group, LLC

Melody A. Carey

+1 917 322 2571

mcarey@rxir.com

About Admedus Limited

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com